In a research report released yesterday, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Sunesis Pharmaceuticals (SNSS) with a $15 price …
Yesterday, Regeneron Pharmaceuticals (REGN) announced second-quarter results, posting EPS of $0.82.
In a research report released today, Roth Capital analyst Joseph Pantginis reiterated coverage with a Buy rating on Ligand Pharmaceuticals (LGND) and a $92.00 price target, following LGND’s second-quarter results, …
In a research report released yesterday, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Cytokinetics Inc. (CYTK) with a $13 price target, following CYTK’s second quarter earnings …
Pharmacyclics (PCYC) yesterday announced 2Q14 results, posting EPS of ($0.49) and revenue of $113.
Yesterday, Roth Capital analyst Joseph Pantginis issued a note in which he reiterated a Buy rating on Regeneron Pharmaceuticals (REGN) and raised his …
In a research note published yesterday, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Ligand Pharmaceuticals (LGND) with a $92 price …
Yesterday, the FDA granted full approval to Pharmacyclics’ (PCYC) for Imbruvica for both treatment naive del17p (poor cytogenetics) CLL patients and all CLL …
In a research report published today, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Stemline Therapeutics, Inc. (STML) with a $62 price target, following today’s news of the opening of STML’s Investigational New …
In reaction to yesterday’s news that Cytori Therapeutics (CYTX), has been selected to supply adipose-derived regenerative cells for the Cardiovascular Cell Therapy Research Network’s (CCTRN) …
